EAP for convalescent plasma no longer enrolling; the FDA authorized emergency use.

See "EAP to EUA transition" box for physician instructions

Learn more

Physician requirements Patients & family Donate plasma Publications Contact

Program Highlights

Uscovidplasma.org included in national archive

The Library of Congress has selected the USCOVIDplasma.org website for inclusion in the nation's historic Coronavirus Web Archive. Mayo Clinic developed the website to facilitate the nation's Expanded Access Program (EAP) for convalescent plasma to treat COVID-19. Selection for the archive demonstrates the significant role of the EAP in the US response to the pandemic, and Mayo Clinic's leadership role. Access to the site will be available at the Library of Congress in Washington, D.C., and on the library's public access website as early as fall 2021.
EAP-related publications

Investigators in the EAP have published two papers demonstrating that convalescent plasma is safe to administer to patients with COVID-19. Several non-peer reviewed manuscripts identify signals of efficacy that may inform future clinical trials on plasma therapy for COVID-19. Other manuscripts are currently submitted for peer review. The publications page includes summaries and links to all journal articles published so far by the EAP team.
Data analysis

The EAP team continues to analyze data from the program and publish its findings, which were an important component of the scientific evidence considered by the U.S. Food and Drug Administration in the decision to issue an Emergency Use Authorization on August 23, 2020, to permit the use of convalescent plasma for treatment in hospitalized patients with COVID-19.

Historical EAP program participation

Participating locations and enrolled providers

Sites
Physicians
Patients
Infused

About this program

Earlier this year, the U.S. Government provided support for a national Expanded Access Program to provide access to convalescent plasma to patients in need across the country. This program provided a pathway for patients with serious or life-threatening COVID-19 access to investigational convalescent plasma outside of clinical trials because no satisfactory alternative therapy options were available.

After evaluating safety and efficacy data for patients transfused in the Mayo Clinic-led EAP program and other existing data, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) to further expand access to convalescent plasma for the treatment of COVID-19 in hospitalized patients.

This EUA allows the use of COVID-19 convalescent plasma to be distributed and used by licensed health care providers to treat adult patients hospitalized with COVID-19.

For more information, refer to the FDA's Fact Sheet for Health Care Providers, which details the process and treatment with convalescent plasma.

What does an EUA provide?

In certain types of emergencies, the FDA can issue an emergency use authorization (EUA) as a temporary measure to provide more timely access to critical medical products that may help during an emergency when there are no adequate, approved and available alternative options.

Treating patients with convalescent plasma under the EUA is easier than the EAP because the physician can simply order the plasma as they would normally even though it has not yet been approved by the FDA as long as the temporary emergency situation as long as the declaration of the public health emergency exists. The EUA is not a clinical trial.

The efficacy of convalescent plasma for the treatment of COVID-19 is still being evaluated.

For more information, refer to the FDA's Fact Sheet for Health Care Providers, which outlines their process for treating patients with COVID-19 convalescent plasma in the EUA.

Who can I contact for more information?

For more information about Expanded Access to Convalescent Plasma for the Treatment of Patients with COVID-19 protocol, please contact:

Michael Joyner, M.D.

Principal Investigator

Mayo Clinic
200 First St. SW
Rochester, MN 55905

View Bio

Email: uscovidplasma@mayo.edu